Table 1 Description of the characteristics of included studies
Study No. | Reference | Year of publication | Country of study | Study design | Control group | Number exposed to Linezolid | Study duration | Number of XDR-TB | LZD dosage | Duration of LZD treatment | Type of anti-TB regimen | HIV infection status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1. | Abbate et al.[35] | 2012 | Argentina | Retrospective study | No | 17 | 2002–2008 | 17 | 600 mg bd | ≥12 months after cc | Individualized | All HIV negative |
2. | Anger et al. [36] | 2010 | USA | Retrospective case series | No | 16 | 2000–2006 | 10 | 600 mg bd 400 mg bd or 600 mg daily | Mean = 15 Median = 16 Range = 1–29 months | Individualized | 3 HIV positive |
3. | Condos et al.[37] | 2008 | USA | Prospective phase 1 clinical trial | No | 6a | 2000–2007 | 6a | 600 mg bd 600 mg daily | Range = 9–26 months | Individualized | All HIV negative |
4. | De Lorenzo et al. [38] | 2012 | Italy | Retrospective study | No | 12 | 2009–2010 | 4 | 600 mg bd (10 patients) 600 mg daily (1 patient) 450 mg bd (1 patient) | Range = 37–100 days Median = 63.5 days | Individualized | 2 HIV negative |
5. | Fortún et al. [39] | 2005 | Spain | Retrospective case series | No | 3b | 1994–2004 | 0 | 600 mg bd | Range = 4–24 months Mean = 12 Median = 12 | Individualized | 1 HIV positive |
6. | Koh et al. [40] | 2009 | South Korea | Retrospective case series | No | 24 | 2007–2008 | 1 | 300 mg daily | Median = 12 months | Individualised | All HIV Negative |
7. | Koh et al. [41] | 2012 | South Korea | Retrospective case series | No | 51 | 2007–2009 | 26 | 300 mg daily | Median = 413 days IQR = 237–622 days | Individualized | All HIV negative |
8. | Lee et al. [42] | 2012 | South Korea | Phase 2a randomized two-group study | No | 38 | 2008–2011 | 41 | 600 mg daily | 22 months | Individualized | All HIV negative |
9. | Liu et al. [43] | 2015 | China | Retrospective case series | No | 16 | 2011–2013 | 16 | 600 mg daily | Range = 3–21 months Mean = 9.53 months | Individualized | All HIV negative |
10. | Migliori et al. [44] | 2009 | Belarus, Germany, Italy, Switzerland | Retrospective non-randomized unblinded observational study | Yes | 85 | 2001–2007 | 12 | 600 mg daily 600 mg bd | Mean = 7 months Median = 3 months | Individualized | 3 HIV positive |
11. | Nam et al. [45] | 2009 | South Korea | Retrospective case series | No | 11 | NR | 4 | 600 mg daily 300 mg bd | Range 3–24 months Mean = 7 months Median 5 months | Individualized | All HIV negative |
12. | Park et al. [46] | 2006 | South Korea | Prospective non-randomized case series | No | 8 | 2003–2006 | 5 | 600 daily 600 bd | Range = 3–18 months Median = 9 months Mean = 11 months | Individualized | All HIV negative |
13. | Roongruangpitayakul et al. [47] | 2013 | Thailand | Retrospective case series | No | 24 | 2009–2012 | 7 | 600 mg daily 300 mg daily | Range = 11.0–21.5 months Mean = 18.7 months | Individualized | All HIV negative |
14. | Schecter et al. [48] | 2010 | USA | Retrospective case series | No | 30 | 2003–2007 | 3 | 600 mg daily | Range = 1–36 months Median = 22 months Mean = 19 months | Individualized | 17 HIV negative |
15. | Singla et al. [49] | 2012 | India | Prospective case series | No | 29 | 2006–2011 | 16 | 600 bd 600 daily | Median = 30 days | Individualized | All HIV negative |
16. | Tang et al. [50] | 2011 | China | Case series | No | 14 | 2009–2010 | 14 | 600 mg bd 600 mg daily | Range= 2–11 months Mean: 6.5 months | Individualised | All HIV negative |
17. | Tang et al. [51] | 2015 | China | Prospective multicenter randomized controlled study | Yes | 33 | 2009–2011 | 65 | 1200 mg daily 300–600 mg daily | Range = 2–24 months | Individualized | All HIV negative |
18. | Tse-Chang et al. [52] | 2013 | Canada | Retrospective case study | No | 13 | 2000–2011 | NR | 600 mg daily | Mean = 8.3 months Range = 1.4–22 months | Individualized | 1 HIV positive |
19. | Udwadia et al. [53] | 2010 | India | Prospective non-randomized case series | No | 18 | 2000–2007 | 7 | 600 mg daily | Mean = 21 months | Individualized | NR |
20. | Villar et al. [54] | 2011 | Portugal | Prospective case series | No | 16 | 2004–2009 | 12 | 600 daily 1200 mg daily | Median = 375 days | Individualized | 6 HIV positive |
21. | Von der Lippe et al. [55] | 2006 | Norway | Retrospective case series | No | 10 | 1998–2002 | 0 | 600 mg bd | Range = 2–10 months Median = 4.25 months | Individualized | 1HIV positive |
22. | Xu et al. [56] | 2012 | China | Retrospective case series | No | 18 | 2007–2010 | 15 | 600 mg bd 900 mg daily | Range =1.5–10 months Median = 6 months | Individualized | All HIV negative |
23. | Zhang et al. [57] | 2014 | China | Retrospective study | Yes | 15 | 2012–2013 | 43 | 600 mg daily | Range = 1–5 months | Individualized | All HIV negative |